ARCHIVES

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

In Brief: Guide Is Late, So RFP Deadline Extended; Real Cancer Mortality Increase Was .7%

January 28, 1977

NCI Phone Number Listings Completed

September 21, 1979

House Committee Proposes $750 Mil. Increase For NIH, supports Bypass

May 4, 1990

NCI Lists ARRA Funding By Organ Site

September 18, 2009

Tobacco Control: Surgeon General Finds Increase In Smoking By Minority Teens

May 1, 1998